Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: big pharma hunts for RNA tech; new data to boost Enhertu in breast cancer; positive pipeline news for Bayer; biosimilars reach a turning point; and Scrip Asks experts about prospects for pharma science and technology in 2022.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 25 February 2022, including: big pharma hunts for RNA tech; new data to boost Enhertu in breast cancer; positive pipeline news for Bayer; biosimilars reach a turning point; and Scrip Asks experts about prospects for pharma science and technology in 2022.
This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Big Pharma Deal Hunters Target RNA Approaches In Race To Build Best Platforms" - Scrip, 21 Feb, 2022.)
(Also see "AstraZeneca and Daiichi Sankyo’s Enhertu Eyes 50% Of Breast Cancer Market Following HER2-Low Data" - Scrip, 21 Feb, 2022.)
(Also see "Bayer's Faith In Pharma Pipeline Paying Off" - Scrip, 21 Feb, 2022.)
(Also see "A US Biosimilar Turning Point Approaches, With Work To Do" - Scrip, 17 Feb, 2022.)
(Also see "Scrip Asks...What Does 2022 Hold For Biopharma? Part 3: Technology And Science" - Scrip, 17 Feb, 2022.)